Conatus Pharmaceuticals Inc., of San Diego, and its research collaborator, Bioreliance, St. Louis-based Sigma-Aldrich Corp.'s biologics and early development services business, presented data at the Society of Toxicology meeting in San Diego describing previously announced results of a six-month evaluation of emricasan, Conatus' orally active, irreversible pan-caspase protease inhibitor, in the Tg.rasH2 humanized mouse model, which is highly prone to developing cancer.